ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Purchases 150,000 Shares of Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De purchased 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were acquired at an average cost of $1.59 per share, with a total value of $238,500.00. Following the completion of the purchase, the chief executive officer directly owned 150,000 shares in the company, valued at $238,500. The trade was a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

ProQR Therapeutics Stock Up 1.2%

Shares of ProQR Therapeutics stock opened at $1.68 on Thursday. The stock’s fifty day moving average is $1.61 and its two-hundred day moving average is $1.68. ProQR Therapeutics N.V. has a 52 week low of $1.33 and a 52 week high of $3.10. The company has a market capitalization of $177.00 million, a PE ratio of -3.36 and a beta of 0.04.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. As a group, research analysts anticipate that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. increased its position in ProQR Therapeutics by 59.6% during the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the period. Persistent Asset Partners Ltd lifted its position in shares of ProQR Therapeutics by 24.5% in the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares during the period. Diadema Partners LP lifted its position in shares of ProQR Therapeutics by 6.2% in the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 9,838 shares during the period. Bank of America Corp DE boosted its stake in shares of ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 11,186 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its stake in shares of ProQR Therapeutics by 15.2% during the third quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 14,549 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PRQR shares. Chardan Capital lowered their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. JonesTrading decreased their price target on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Wall Street Zen cut ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings downgraded ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, ProQR Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.